Global Ultomiris Drug Market Size Likely to Grow at a CAGR of 31.52% By 2034

Market Size and Growth

As per the Ultomiris Drug Market size analysis conducted by the CMI team, the ultomiris drug market is expected to record a CAGR of 31.52% from 2025 to 2034. In 2025, the market size was USD 5.47 Billion. By 2034, the valuation is anticipated to reach USD 64.12 Billion.

Overview

As per the industry experts at CMI, the global ultomiris drug market will witness a whopping CAGR between 2025 and 2034. This could be attributed to the rise in demand for various long-acting treatments for rare disorders, especially paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). North America holds the largest market share due to speedy adoption of ultomiris drug by the U.S. and Canada. Hospital pharmacies dominate as far as distribution channels are concerned.

Key Trends & Drivers

• Long-Acting Treatment Preference to Spell Growth: Ultomiris does offer a long-acting dosing interval (every 8 weeks), which enhances patient convenience and compliance as compared to the shorter-acting alternatives. Ultomiris is also known for demonstrating robust clinical performance along with a well-established safety profile.

• Approval by Regulatory Bodies to Catalyze Growth: The U.S. FDA had approved ultomiris for adults suffering from gMG in the year 2022. Since then, the drug has strengthened its position in the neurology sector. The FDA also conducted a review on priority in March 2024 for ultomiris in NMOSD. These approvals and reviews are bound to take the ultomiris market to the next level in the forecast period.

Report Scope

SWOT Analysis

• Strengths: Ultomiris has demonstrated a manageable safety profile and efficacy in the treatment of gMG and PNH. With the market for rare disease therapies growing on the whole, a favorable environment is created for ultomiris. Also, ongoing research coupled with clinical trials is bound to result in extra approved indications for ultomiris drug, thereby bolstering its market potential.

• Weaknesses: Ultomiris is quite expensive. This is likely to apply brakes to its accessibility for certain patients, particularly in the resource-limited settings. Moreover, the need for intravenous infusion could be a barrier to patient convenience and preference.

• Opportunities: Ultomiris has a huge potential for growth in the emerging markets with expansion of healthcare infrastructure and awareness regarding rare diseases. Furthermore, a subcutaneous formulation on the part of ultomiris is likely to offer a convenient route of administration for the patients. Also, exploration of the potential of combining ultomiris with the other therapies for improving treatment outcomes could fetch more revenue.

• Threats: There are pharmaceutical companies developing competing therapies for gMG and PNH, which is likely to erode the market share of ultomiris. Also, the development as well as the approval of ultomiris’ biosimilar version is likely to adversely affect the market pricing and share.

List of the prominent players in the Ultomiris Drug Market:

• AstraZeneca
• Xencor Inc.
• Chugai Pharmaceutical
• Argenx
• Alexion Pharmaceuticals
• Others

The Ultomiris Drug Market is segmented as follows:

By Indication

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Generalized Myasthenia Gravis (gMG)
• Neuromyelitis Optica Spectrum Disorder (NMOSD)

By End-use

• Adult
• Pediatric

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America